(Q34338202)

1 August 2017

1 reference

title

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs (English)

1 reference

1 August 2017

0 references

1 reference

Miyamoto S

1

1 reference

1 August 2017

Duncan GE

series ordinal

2

1 reference

1 August 2017

Marx CE

series ordinal

3

1 reference

1 August 2017

Lieberman JA

series ordinal

4

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 January 2005

1 reference

1 August 2017

1 reference

1 August 2017

10

1 reference

1 August 2017

79-104

1 reference

1 August 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.mp.4001556

1 August 2017

0 references

cites work

Broad therapeutic uses of atypical antipsychotic medications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Catching up on schizophrenia: natural history and neurobiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Antipsychotic drug doses and neuroleptic/dopamine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Dopamine receptors and the dopamine hypothesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Blunted brain metabolic response to ketamine in mice lacking D(1A) dopamine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Changes in apomorphine-induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not with increases in D-1 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Acute and chronic haloperidol treatment: Comparison of effects on nigral dopaminergic cell activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Differential Effects of Classical and Atypical Antipsychotic Drugs on A9 and A10 Dopamine Neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Failure of chronic haloperidol to induce depolarization inactivation of dopamine neurons in unanesthetized rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Haloperidol does not produce dopamine cell depolarization-block in paralyzed, unanesthetized rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Dose dependent occupancy of central dopamine D2 receptors by the novel neuroleptic CP-88,059-01: a study using positron emission tomography and 11C-raclopride.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Risperidone in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Serotonergic basis of antipsychotic drug effects in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Clozapine is a partial agonist at cloned, human serotonin 5-HT1A receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Biological perspectives. Aripiprazole: a third generation of antipsychotics begins?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Effects of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) after repeated administration on a conditioned avoidance response (CAR) in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

8-OH-DPAT, a 5-HT1A agonist and ritanserin, a 5-HT2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Serotonin model of schizophrenia: emerging role of glutamate mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Effects of antipsychotic drugs on dopamine and serotonin contents and metabolites, dopamine and serotonin transporters, and serotonin1A receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Olanzapine, quetiapine, and risperidone: long-term effects on monoamine transporters in rat forebrain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Recent advances in the phencyclidine model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Glutamate receptor dysfunction and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

The glutamatergic dysfunction hypothesis for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

M100907 and clozapine, but not haloperidol or raclopride, prevent phencyclidine-induced blockade of NMDA responses in pyramidal neurons of the rat medial prefrontal cortical slice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl- d -aspartate receptor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Chronic treatment with haloperidol diminishes the phencyclidine-induced sensorimotor gating deficit in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

The role of glutamate receptors in antipsychotic drug action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Chronic administration of haloperidol and olanzapine attenuates ketamine-induced brain metabolic activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Effect of chronic clozapine administration on [3H]MK801-binding sites in the rat brain: a side-preference action in cortical areas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Antipsychotic drug regulation of AMPA receptor affinity states and GluR1, GluR2 splice variant expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Chronic haloperidol and clozapine administration increases the number of cortical NMDA receptors in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Regulation of ionotropic glutamate receptors in the rat brain in response to the atypical antipsychotic seroquel (quetiapine fumarate).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Long-term effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: implications for antipsychotic drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

The effect of chronic haloperidol treatment on glutamate receptor subunit (GluR1, GluR2, KA1, KA2, NR1) mRNAs and glutamate binding protein mRNA in rat forebrain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Regulation of NMDA receptor subunit messenger RNA levels in the rat brain following acute and chronic exposure to antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Clozapine and haloperidol differentially affect AMPA and kainate receptor subunit mRNA levels in rat cortex and striatum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Modulation of glutamate receptors in response to the novel antipsychotic olanzapine in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Effects of long-term antipsychotic treatment on NMDA receptor binding and gene expression of subunits

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Antipsychotic drug treatment induces differential gene expression in the rat cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Chromogranin A, an "on/off" switch controlling dense-core secretory granule biogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Synaptotagmins: C2-domain proteins that regulate membrane traffic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Calcineurin and intracellular Ca2+-release channels: regulation or association?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Further evidence that behavioral tests and neuropeptide mRNA and tissue level alterations can differentiate between typical and atypical antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Aripiprazole: A New Atypical Antipsychotic Drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Neuropsychologic deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Factors influencing relapse in the long-term course of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Pharmacologic treatment of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

The new and evolving pharmacotherapy of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Atypical antipsychotics: are some more atypical than others?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

A meta-analysis of the efficacy of second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Patient response and resource management: another view of clozapine treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Discovering the neural basis of human social anxiety: a diagnostic and therapeutic imperative.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Negative symptoms in schizophrenia: neurobiological models and treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Neuroleptic treatment of negative symptoms in schizophrenic patients. Efficacy problems and methodological difficulties

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Cognitive function in schizophrenia--do neuroleptics make a difference?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Does risperidone improve verbal working memory in treatment-resistant schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Improvement of cognitive dysfunction after treatment with second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Another view of therapy for cognition in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Atypical antipsychotic drugs improve cognition in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Management of treatment resistance in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Quetiapine: a review of its safety in the management of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Atypical antipsychotics and weight gain--a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Aripiprazole: does partial dopaminergic agonism translate into clinical benefits?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

NNC 01-0687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Modulation of memory fields by dopamine D1 receptors in prefrontal cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Dopamine D4 receptors elevated in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Direct determination of dopamine D4 receptors in normal and schizophrenic postmortem brain tissue: a [3H]NGD-94-1 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Selective dopamine D4 receptor antagonists reverse apomorphine-induced blockade of prepulse inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Current and novel approaches to the drug treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Dopamine D3 receptor ligands with antagonist properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Selective antagonism at dopamine D3 receptors enhances monoaminergic and cholinergic neurotransmission in the rat anterior cingulate cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

The emerging role of glutamate in the pathophysiology and treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Amelioration of negative symptoms in schizophrenia by glycine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Free D-aspartate and D-serine in the mammalian brain and periphery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

D-serine added to antipsychotics for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Modulation of N-methyl-D-aspartate receptor function by glycine transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Glial transporters for glutamate, glycine and GABA I. Glutamate transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Expression of excitatory amino acid transporter transcripts in the thalamus of subjects with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Striatal excitatory amino acid transporter transcript expression in schizophrenia, bipolar disorder, and major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Decreased gene expression of glial and neuronal glutamate transporters after chronic antipsychotic treatment in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Differential behavioural and neurochemical effects of competitive and non-competitive NMDA receptor antagonists in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

The non-NMDA glutamate receptor antagonist GYKI 52466 counteracts locomotor stimulation and anticataleptic activity induced by the NMDA antagonist dizocilpine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

DNQX inhibits phencyclidine (PCP) and ketamine induction of the hsp70 heat shock gene in the rat cingulate and retrosplenial cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Atypical antipsychotic-like effect of AMPA receptor antagonists in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Dopamine-induced oxidative stress in neurons with glutathione deficit: implication for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Glutathione and signal transduction in the mammalian CNS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Pharmacologic strategies for augmenting cognitive performance in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

The role of norepinephrine in the pathophysiology of cognitive disorders: potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Alpha 2-adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Clonidine improves memory function in schizophrenia independently from change in psychosis. Preliminary findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Comparison of the binding activities of some drugs on alpha 2A, alpha 2B and alpha 2C-adrenoceptors and non-adrenergic imidazoline sites in the guinea pig.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Guanfacine treatment of cognitive impairment in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Mechanism of peripheral noradrenergic stimulation by clozapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Prefrontal neurons and the genetics of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Catechol O-methyltransferase inhibitor tolcapone has minor influence on performance in experimental memory models in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Cognitive improvement during Tolcapone treatment in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Neuroscience. Deconstructing schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Quality of life as a predictor for change in disability in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Cognitive effects of nicotine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Nicotinic agonists and psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Schizophrenia, sensory gating, and nicotinic receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Intragastric DMXB-A, an alpha7 nicotinic agonist, improves deficient sensory inhibition in DBA/2 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Effects of alpha 4/beta 2- and alpha 7-nicotine acetylcholine receptor agonists on prepulse inhibition of the acoustic startle response in rats and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Galantamine for treatment-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Donepezil in schizophrenia--is it helpful? An experimental design case study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Donepezil for memory dysfunction in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Muscarinic receptors as a target for drugs treating schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Psychotic reactions following cannabis use in East Indians.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Cannabis induced dopamine release: an in-vivo SPECT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Endocannabinoid signalling in the blood of patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Blockade of cannabinoid receptors by SR141716 selectively increases Fos expression in rat mesocorticolimbic areas via reduced dopamine D2 function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

The role of neurotensin in the pathophysiology of schizophrenia and the mechanism of action of antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Neurotensin: an endogenous antipsychotic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Neurotensin is an antagonist of the human neurotensin NT2 receptor expressed in Chinese hamster ovary cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

The effects of systemic NT69L, a neurotensin agonist, on baseline and drug-disrupted prepulse inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

L-deprenyl in treating negative symptoms of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Anti-apoptotic function of propargylamine inhibitors of type-B monoamine oxidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Immunohistochemical localization of PDE10A in the rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7-Nitroindazole and methylene blue, inhibitors of neuronal nitric oxide synthase and NO-stimulated guanylate cyclase, block MK-801-elicited behaviors in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Nitric oxide synthase inhibition blocks phencyclidine-induced behavioural effects on prepulse inhibition and locomotor activity in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Effects of modulation of nitric oxide on acoustic startle responding and prepulse inhibition in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Nitric oxide synthase inhibitors attenuate phencyclidine-induced disruption of prepulse inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Neuroactive neurosteroids as endogenous effectors for the sigma1 (sigma1) receptor: pharmacological evidence and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Effects of dehydroepiandrosterone and its sulfate on brain tissue in culture and on memory in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Dehydroepiandrosterone and its sulfated derivative reduce neuronal death and enhance astrocytic differentiation in brain cell cultures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Dehydroepiandrosterone: a potential signalling molecule for neocortical organization during development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Neuroprotection by dehydroepiandrosterone-sulfate: role of an NFkappaB-like factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Dehydroepiandrosterone (DHEA) protects hippocampal cells from oxidative stress-induced damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Dehydroepiandrosterone and its sulfate enhance memory retention in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Dehydroepiandrosterone sulfate improves memory in aging mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Memory-enhancing effects in male mice of pregnenolone and steroids metabolically derived from it.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

The effects of neurosteroids on acquisition and retention of a modified passive-avoidance learning task in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Dehydroepiandrosterone sulfate attenuates dizocilpine-induced learning impairment in mice via sigma 1-receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Use of dehydroisoandrosterone in psychiatric treatment; a preliminary survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Use of dehydroisoandrosterone in psychiatric practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Neuroactive steroids: new biomarkers of cognitive aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Effects of sigma(1) receptor agonist SA4503 and neuroactive steroids on performance in a radial arm maze task in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Neurosteroids ameliorate conditioned fear stress: an association with sigma receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Longitudinal study of brain morphology in first episode schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Progressive decrease of left superior temporal gyrus gray matter volume in patients with first-episode schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Progressive decrease of left Heschl gyrus and planum temporale gray matter volume in first-episode schizophrenia: a longitudinal magnetic resonance imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Neurotrophic factors and the maldevelopmental hypothesis of schizophrenic psychoses. Review article.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Implications of normal brain development for the pathogenesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Pharmacogenetic prediction of clozapine response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

In vivo occupancy of striatal and temporal cortical D2/D3 dopamine receptors by typical antipsychotic drugs. [123I]epidepride single photon emission tomography (SPET) study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Non-equipotent doses partly explain differences among antipsychotics - implications of PET studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

The relationship between D 2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Chronic treatments with zotepine, thioridazine, and haloperidol affect apomorphine-elicited stereotypic behavior and striatal 3H-spiroperidol binding sites in the rat

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Depolarization inactivation of dopamine neurons: an artifact?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Striatal extracellular dopamine levels in rats with haloperidol-induced depolarization block of substantia nigra dopamine neurons.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Behavioral evidence of depolarization block of dopamine neurons after chronic treatment with haloperidol and clozapine.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Actions of 5-hydroxytryptamine on neurons of the rat cingulate cortex.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

An integrated view of pathophysiological models of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Differential effects of haloperidol and clozapine on ionotropic glutamate receptors in rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Intracellular neuronal calcium sensor proteins: a family of EF-hand calcium-binding proteins in search of a function

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Network interactions in schizophrenia - therapeutic implications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Important issues in the drug treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Negative symptoms: diagnosis, treatment and prognosis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Effects of dihydrexidine, a full dopamine D-1 receptor agonist, on delayed response performance in chronic low dose MPTP-treated monkeys

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

D(1) receptors in prefrontal cells and circuits

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Atypical antipsychotic-like effects of the dopamine D3 receptor agonist, (+)-PD 128,907

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

D-cycloserine added to clozapine for patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Glycine uptake governs glycine site occupancy at NMDA receptors of excitatory synapses.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Reversal of phencyclidine-induced hyperactivity by glycine and the glycine uptake inhibitor glycyldodecylamide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Glycyldodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake: implications for schizophrenia and substance abuse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

The role of dopamine and AMPA/kainate receptors in the nucleus accumbens in the hypermotility response to MK801

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Facilitative effects of the ampakine CX516 on short-term memory in rats: correlations with hippocampal neuronal activity.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Facilitative effects of the ampakine CX516 on short-term memory in rats: enhancement of delayed-nonmatch-to-sample performance.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Overlap of dopaminergic, adrenergic, and serotoninergic receptors and complementarity of their subtypes in primate prefrontal cortex

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

The potential of subtype-selective neuronal nicotinic acetylcholine receptor agonists as therapeutic agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Elevated endogenous cannabinoids in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Blockade of cannabinoid (CB1) receptors by 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Repeated administration of the neurotensin receptor antagonist SR 48692 differentially regulates mesocortical and mesolimbic dopaminergic systems.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Treatment of negative symptoms in schizophrenia and schizoaffective disorder by selegiline augmentation of antipsychotic medication. A pilot study examining the role of dopamine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Selegiline augmentation of antipsychotics for the treatment of negative symptoms in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Deprenyl augmentation for treating negative symptoms of schizophrenia: a double-blind, controlled study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Involvement of nitric oxide in phencyclidine-induced hyperlocomotion in mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Methylene blue adjuvant therapy of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via sigma receptors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Further studies on endocrine treatment in adolescence and early adult life

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Role of pregnenolone, dehydroepiandrosterone and their sulfate esters on learning and memory in cognitive aging

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

When neurotrophic factors get on your nerves: therapy for neurodegenerative disorders.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Advances in the pharmacogenetic prediction of antipsychotic response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001556

7 January 2021

Identifiers

DOI

10.1038/SJ.MP.4001556

1 reference

1 August 2017

1 reference